Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicentric prospective study analyzing efficacy and safety of pembrolizumab/axitinib combination in metastatic renal cell carcinoma

Next Previous
Trial Profile

A multicentric prospective study analyzing efficacy and safety of pembrolizumab/axitinib combination in metastatic renal cell carcinoma

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 03 Apr 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Axitinib (Primary) ; Pembrolizumab (Primary)
  • Indications Renal cell carcinoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ProPAXI

Most Recent Events

  • 18 Feb 2023 Results ( January 2021 to September 2022) evaluating the safety of Pembrolizumab/axitinib (PAXI) combination in the real-world experience, presented at the 2023 Genitourinary Cancers Symposium.
  • 04 Nov 2022 New trial record
  • 13 Sep 2022 Results presented at the 47th European Society for Medical Oncology Congress

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top